These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20347613)

  • 1. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
    Janeway KA; Grier HE
    Lancet Oncol; 2010 Jul; 11(7):670-8. PubMed ID: 20347613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
    Gallegos-Castorena S; Martínez-Avalos A; Mohar-Betancourt A; Guerrero-Avendaño G; Zapata-Tarrés M; Medina-Sansón A
    Pediatr Hematol Oncol; 2007 Sep; 24(6):403-8. PubMed ID: 17710657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemotherapy of osteosarcoma].
    Winkler K; Bieling P; Bielack S
    Z Orthop Ihre Grenzgeb; 1992; 130(4):285-9. PubMed ID: 1413973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.
    Ferrari S; Palmerini E; Staals E; Abate ME; Longhi A; Cesari M; Balladelli A; Pratelli L; Bacci G
    J Chemother; 2009 Apr; 21(2):205-10. PubMed ID: 19423475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.
    Ferrari S; Bielack SS; Smeland S; Longhi A; Egerer G; Sundby Hall K; Donati D; Kevric M; Brosjö O; Comandone A; Werner M; Monge O; Palmerini E; Berdel WE; Bjerkehagen B; Paioli A; Lorenzen S; Eriksson M; Gambarotti M; Tunn PU; Jebsen NL; Cesari M; von Kalle T; Ferraresi V; Schwarz R; Bertulli R; Kasparek AK; Grignani G; Krasniqi F; Sorg B; Hecker-Nolting S; Picci P; Reichardt P
    Tumori; 2018; 104(1):30-36. PubMed ID: 29218692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
    Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C;
    Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Goal and results of the COSS study].
    Flege S; Bielack S
    Handchir Mikrochir Plast Chir; 2004 Oct; 36(5):282-8. PubMed ID: 15503258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
    J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
    J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
    J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma.
    Rosen G
    Cancer Treat Res; 1993; 62():49-54. PubMed ID: 8096759
    [No Abstract]   [Full Text] [Related]  

  • 14. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
    Patel SR; Papadopolous N; Raymond AK; Donato M; Seong CM; Yasko AW; Lewis VO; Lin PP; Champlin R; Benjamin RS
    Cancer; 2004 Jul; 101(1):156-63. PubMed ID: 15222001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
    Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
    Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma.
    Longhi A; Macchiagodena M; Vitali G; Bacci G
    J Pediatr Hematol Oncol; 2003 Apr; 25(4):292-6. PubMed ID: 12679642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.
    Koch Nogueira PC; Hadj-Aïssa A; Schell M; Dubourg L; Brunat-Mentigny M; Cochat P
    Pediatr Nephrol; 1998 Sep; 12(7):572-5. PubMed ID: 9761357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteogenic progenitor cell potency after high-dose chemotherapy (COSS-96).
    Jäger M; Schultheis A; Westhoff B; Krauspe R
    Anticancer Res; 2005; 25(2A):947-54. PubMed ID: 15868932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteosarcoma: review of the past, impact on the future. The American experience.
    Jaffe N
    Cancer Treat Res; 2009; 152():239-62. PubMed ID: 20213394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neoadjuvant treatment in osteosarcomas].
    Kalifa C; Brugières L; Le Deley MC
    Bull Cancer; 2006 Nov; 93(11):1115-20. PubMed ID: 17145581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.